DexCom Posts Higher Revenue, Operating Income, Net Income, and Diluted EPS Year-Over-Year on Both Reporting Windows in Interim Filing

Bottom line

- For the three-month reporting period and the six-month year-to-date period, both top-line revenue and bottom-line earnings moved higher than the prior-year comparative, while staying profitable on every reported window. - Revenue from Contract with Customer, Excluding Assessed Tax came in at $1,308,400,000 USD on the three-month window and at $2,500,300,000 USD for the six-month year-to-date window, with both readings higher than the prior-year three-month figure of $1,157,100,000 USD and the prior-year six-month figure of $2,193,100,000 USD respectively. - Operating Income (Loss) registered at $318,300,000 USD for the three months and at $573,600,000 USD for the six-month year-to-date window, with both readings higher than the prior-year three-month figure of $212,600,000 USD and the prior-year six-month figure of $346,300,000 USD respectively, and the transition on each window remains profit to profit. - Net Income (Loss) Attributable to Parent was reported at $249,100,000 USD on the three-month window and at $448,600,000 USD on the six-month window, each higher than the prior-year three-month figure of $179,800,000 USD and the prior-year six-month figure of $285,200,000 USD respectively, with the transition on each window remaining profit to profit. - Earnings Per Share, Diluted was reported at $0.64 per diluted share USD/SHARES for the three-month window and at $1.15 per diluted share USD/SHARES for the six-month year-to-date window, with both readings higher than the prior-year three-month figure of $0.45 per diluted share USD/SHARES and the prior-year six-month figure of $0.71 per diluted share USD/SHARES respectively, and the transition on each window remains profit to profit.

- Management frames the filing as an interim report under U.S. GAAP, prepared in accordance with the instructions to the form type and the SEC’s interim Regulation S-X rules, and notes that the accompanying unaudited condensed consolidated financial statements include only normal recurring adjustments considered necessary for a fair presentation. - Management adds that operating results for the three and six months covered by this report are not necessarily indicative of the results that may be expected for the full fiscal year ending December of the year referenced in the six months ended June 30, 2026.

- Cross-checking against the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows insight, the same profit-to-profit pattern across both the quarter and half-year windows shows up here as well, though the two issuers operate in unrelated industries and no peer-level rate-of-change is implied. - Taken together with the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing write-up, the directional read on revenue, operating income, and diluted EPS year-over-year here matches what that independent filing describes, without any shared driver being implied.

- None observed within the reported results window; each of the four headline metrics compares higher than the prior-year reading on both the three-month and six-month windows, and each remains firmly profitable.

UNKNOWN: - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension.

Financial performance

- Revenue from Contract with Customer, Excluding Assessed Tax was $1,308,400,000 USD for the three months ended (omitted) through (omitted), compared with $1,157,100,000 USD for the prior-year three-month window — a higher figure year over year, consistent with the authorized direction. For the six-month year-to-date view, the line printed $2,500,300,000 USD against $2,193,100,000 USD for the same window a year earlier, again higher year over year. - Operating Income (Loss) was $318,300,000 USD for the three-month reporting period versus $212,600,000 USD for the prior-year quarter, a profit on both sides and a higher profit this year.

The half-year picture shows $573,600,000 USD against $346,300,000 USD, profit on both sides and higher this year. - Net Income (Loss) Attributable to Parent was $249,100,000 USD for the quarter, up from $179,800,000 USD a year earlier, with both periods in profit. The year-to-date figure was $448,600,000 USD versus $285,200,000 USD for the prior year-to-date, again profit on both sides and higher this time.

45 per diluted share USD/SHARES for the prior-year quarter, profit on both sides and higher. 71 per diluted share USD/SHARES, again profit on both sides and higher. S.

GAAP for interim financial information and the instructions to Form 10-Q and Article (omitted) of SEC Regulation S-X, and explicitly cautions that the three- and six-month figures should be read alongside the audited financial statements described in Item 8 of the most recent Annual Report on Form (omitted). Management also notes that certain prior-period amounts have been reclassified to conform to the current period presentation, and that foreign-currency translation differences flow through other comprehensive income rather than the income statement.

- Management addresses the qualitative accounting context rather than giving forward guidance: estimates and assumptions affect reported amounts in areas such as pharmacy rebates, inventory reserves, loss contingencies, and the worldwide tax provision, and the company places cash and investments with a few major financial institutions under diversification and maturity guidelines that are reviewed periodically. Channel-of-disclosure language, trademark notices for the Dexcom family of marks, and concentration-of-credit-risk commentary sit in the same narrative block.

- No forward-looking guidance, target range, or forecast is provided in the cited narrative for revenue, operating income, net income, or diluted EPS for either the quarter or the half-year; readers should treat any outlook as outside this filing. - No peer or industry benchmark is disclosed alongside the reported figures. - No segment-level breakdown of revenue, operating income, net income, or diluted EPS is provided.

- The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension.

Operating drivers and segments

DexCom, Inc. reports as a single medical device segment focused on the design, development, and commercialization of continuous glucose monitoring systems for diabetes and metabolic health management, and the unaudited condensed consolidated financial statements under Note 1 do not break out separate operating segments in this filing. Reported revenue moved higher on both reporting windows versus the prior-year comparatives, and operating income moved higher on both windows as well, with each line retaining a profit-to-profit transition rather than a swing to a loss. The direction and transition relations are limited to those authorized for this filing; no margin percentages or unit-economics have been computed here, because the catalog supplies only the four revenue and operating-income figures. The growth in the six-month period's revenue and operating income tracks in the same direction as the three-month period's revenue and operating income versus their respective priors, and the prior-year comparatives themselves were both positive rather than loss-making. No segment-level revenue or operating-income disclosures for distinct product families, geographies, or channels appear in the evidence tied to this section, so a multi-segment view cannot be presented without inventing a split.

Management frames Dexcom's business as a single continuous glucose monitoring franchise, citing the design, development, and commercialization pipeline for patients, caregivers, and clinicians globally, and notes that the unaudited condensed consolidated financial statements are prepared under U.S. GAAP for interim financial information in accordance with the instructions to Form 10-Q. Management states that all adjustments included are limited to normal recurring adjustments considered necessary for a fair presentation. The cautionary statement regarding forward-looking statements under Section 13 cautions that any forward-looking declarations regarding operations, financial condition, prospects, and business strategies are based on intent, beliefs, expectations, and assumptions as of the date of the report and are not guarantees of future performance, and that actual results could differ materially because of risks including preliminary information subject to further adjustment and risks detailed in the Annual Report on Form as referenced in Item 8. The fair-value hierarchy notes under Level 1, Level 2, and Level 3 describe how financial instruments are classified, and Note 5 addresses stockholders' equity disclosures. Management does not, in the narrative supplied for this section, attribute the period-over-period movement in revenue or operating income to any single cause such as pricing, volume, mix, currency, or cost program. The filing evidence does not attribute this change to any single cause.

Independent analyst inference in this section is bounded by what the catalog authorizes: revenue and operating income are both higher than their respective prior-year comparatives on both the three-month and six-month windows, and each prior-year comparative was itself positive rather than a loss. The currency of the comparison is profit-to-profit growth on both windows. Outside those authorized relations, no independent driver analysis — pricing, volume, gross margin, operating expense leverage, geographic mix, or product-mix — can be asserted from the filing evidence, because the underlying figures behind such an analysis are not in the catalog and no peer or industry comparison is available. The filing evidence contains no peer or industry comparison. Readers looking for a multi-issuer cross-check can compare the directional pattern with Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing or with Reinsurance Group of America Inc Posts Higher Revenue and Net Income in Filing, both of which report the same authorized profit-to-profit direction on revenue and the income metric. The filing does not break out a segment-level operating margin, a contribution margin, or a cost-of-revenue line for this section, so a margin walk, an opex-leverage claim, or a driver-based decomposition is not supportable from the filing evidence.

Cash flow and capital

The six-month year-to-date window for DEXCOM INC under 10-Q (period-ended-2026-06-30, accession 0001093557-26-000143) shows operating cash generation improving against the prior-year comparative, with the period inflow of $794,800,000 running above the prior-year inflow of $486,800,000. Investing activity for the same the six months ended June 30, 2026 remained a source of liquidity, recorded at $31,300,000, which the filing shows lower than the prior-year comparable of $36,600,000. Financing activity is the swing line of the cash flow statement this period: the figure moved from a positive $10,800,000 in the six months ended June 30, 2025 to a use of cash of -$632,300,000 in the six months ended June 30, 2026, marking the only directional reversal across the three activity lines relative to the comparative.

On the capital-allocation side, the most visible change is the re-entry of share repurchases. Payments for Repurchase of Common Stock were nil in the six months ended June 30, 2025 per the filing, then reappeared at $603,600,000 in the six months ended June 30, 2026, indicating that DEXCOM INC (DXCM) restarted buybacks after a period with no such outflow. Capital expenditure intensity moved the other way: Payments to Acquire Property, Plant, and Equipment for the six months ended June 30, 2026 were $161,300,000, lower than the prior-year $181,100,000, suggesting a more measured build-out cadence even as the company continued to invest. The combination of higher operating cash generation, resumed repurchases, and lower capital spending is consistent with a posture that funds ongoing operations and buybacks from internally generated cash rather than from new financing inflows. The year-to-date financing outflow itself is consistent with that mix, though the filing does not apportion that outflow between buybacks and other financing items. The filing evidence does not attribute this change to any single cause.

The balance sheet snapshot at the balance sheet date of June 30, 2026 reinforces the liquidity picture. Cash and Cash Equivalents, at Carrying Value stood at $1,105,000,000, providing a working-currency cushion against the financing use of cash discussed above. On the obligations side, Accounts Payable, Trade, Current was reported at $423,800,000 and Accounts Payable and Other Accrued Liabilities, Current at $2,191,500,000, reflecting the routine short-term obligations associated with operations during the window. The filing treats these as reported balances without a peer or industry comparison; The filing evidence contains no peer or industry comparison. is the only supported framing relative to comparable manufacturers.

For context on how an interim cash flow profile can shift between periods, readers may also find the pattern in Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows useful as a side-by-side reference. Within DEXCOM INC's own disclosures, the fair-value hierarchy in the cited note discusses Level 1, Level 2, and Level 3 instruments for disclosure purposes only, and Note 1 and Note 5 are referenced for policy and equity context; neither note is cited here because the cash-flow and capital-allocation picture does not rest on fair-value or equity movements. Management does not, in the quoted source narrative, offer a story for why financing turned into a use of cash or why buybacks resumed; the year-over-year direction is the only authorized inference.

Peer and historical context

- The peer-comparison dimension is not supported by the filing evidence. The cited narrative covers fair-value hierarchy classifications, foreign currency hedging, non-marketable equity investments, and recent accounting pronouncements, but it does not name any peer company, industry index, or market basket against which DEXCOM INC's results can be benchmarked. The filing evidence contains no peer or industry comparison.

- Historical comparison is supported only through the year-over-year relations authorized for this filing, drawn from the period-ended-2026-06-30 reporting windows under accession 0001093557-26-000143. On the three-month window (the three months ended June 30, 2026 vs the three months ended June 30, 2025), revenue from contracts with customers moved higher year over year, operating income moved higher while remaining profitable, and net income attributable to parent moved higher while remaining profitable; the diluted earnings-per-share line item likewise moved higher while remaining profitable across both windows.

On the six-month year-to-date window (the six months ended June 30, 2026 vs the six months ended June 30, 2025), revenue moved higher, operating income moved higher while remaining profitable, net income moved higher while remaining profitable, and net cash provided by operating activities moved higher while remaining positive on both sides. The filing evidence does not attribute this change to any single cause. - The cash-flow comparison contains an authorized directional shift worth flagging: net cash provided by financing activities moved lower year over year on the half-year window, transitioning from a positive prior-year comparative to a negative current-period position.

Net cash provided by investing activities also moved lower on the half-year window, but remained positive on both sides. Payments for the repurchase of common stock moved higher, transitioning from a zero prior-year comparative to a positive current-period position, while payments to acquire property, plant, and equipment moved lower while remaining positive on both sides. The filing evidence does not attribute this change to any single cause.

- Readers comparing DEXCOM INC's interim results to broader sector filings of similar vintage may find contextual color in adjacent Lizely coverage like Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing and REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, but those are cross-issuer orientation points, not a controlled peer set within the filing evidence.

The filing evidence contains no peer or industry comparison. - The 10-Q filing under accession 0001093557-26-000143 references prior-period accounting-policy detail through Note 1 and stockholders'-equity disclosures through Note 5, and fair-value classifications through Level 1, Level 2, and Level 3; the filing also points to Item 8 in the most recent annual report and to the Section-thirteen disclosure referenced in Section 13. None of those references provide a peer-set benchmark, so no head-to-head metric ranking can be asserted from this section's evidence.

The filing evidence contains no peer or industry comparison.

Scenario analysis

- Reported (frozen) top-line: Revenue from Contract with Customer, Excluding Assessed Tax for the six months ended June 30, 2026 was $2,500,300,000 USD, higher than $2,193,100,000 USD in the six months ended June 30, 2025. - Reported (frozen) top-line: Revenue from Contract with Customer, Excluding Assessed Tax for the three months ended June 30, 2026 was $1,308,400,000 USD, higher than $1,157,100,000 USD in the three months ended June 30, 2025. - Reported (frozen) bottom-line: Net Income (Loss) Attributable to Parent for the six months ended June 30, 2026 was $448,600,000 USD (profit), higher than $285,200,000 USD (profit) in the six months ended June 30, 2025. - Reported (frozen) bottom-line: Net Income (Loss) Attributable to Parent for the three months ended June 30, 2026 was $249,100,000 USD (profit), higher than $179,800,000 USD (profit) in the three months ended June 30, 2025. - The base view simply carries the filed six-month and three-month trajectories forward, assuming reported revenue growth and reported profit-to-profit net income growth both continue on each window. The filing evidence does not attribute this change to any single cause. - Counter-evidence against the base view is thin inside the filing: the quoted hedging and fair-value disclosures do not point to a structural drag, and non-marketable investment unrealised moves were described as not significant. The filing evidence does not attribute this change to any single cause. - Unknowns that could disturb the base: the filing contains no peer or industry comparison and no segment-level detail for revenue or net income. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

- Upside rests on the same authorized comparators used in the base: higher reported revenue and higher reported profit-to-profit net income on both the three-month and six-month windows. - Reinforcing context inside the filing: foreign-currency hedging impact for both periods was described as not significant, so reported top-line translation risk does not appear to be a visible offset to growth in the cited evidence. - Reinforcing context inside the filing: cumulative upward adjustments on non-marketable equity investments were reported while cumulative downward adjustments and impairments were described as not significant, suggesting no large mark-down headwind surfaced in the period covered by the disclosure. - Reinforcing context inside the filing: Level 1, Level 2, and Level 3 fair-value inputs are described, and no significant impairment losses on non-financial assets measured at fair value on a non-recurring basis were reported. - Upside risks: The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension. - Counterpoint: an upside narrative cannot be elevated to a forecast — the filing's authorized comparators describe reported direction only, not magnitude, and no segment mix is disclosed that would extrapolate a higher path.

- Downside read on the same reported comparators: if reported revenue growth or reported profit-to-profit net income growth slows, reverses, or turns to a loss on either window, the path above would not hold. The filing itself does not authorize a negative direction for revenue or net income; any deterioration framing here is scenario-only and not a forecast. The filing evidence does not attribute this change to any single cause. - Downside-relevant items to watch, drawn only from the cited evidence: cumulative downward adjustments on non-marketable equity investments were described as not significant to date, which is supportive, but a future observable price decline could surface through the measurement alternative. - Downside-relevant items: Level 3 non-financial long-lived assets are measured at fair value only when an impairment is recognized; impairment is therefore the disclosed downside trigger for goodwill, intangibles, and property and equipment. - Downside-relevant items: foreign-currency derivative gains and losses are recognised in other income (expense), net and offset related monetary exposures; a widening hedge ineffectiveness gap would be a downside signal, but the filing characterises the impact as not significant for the cited periods. - Outside the filing: The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension. - The scenario therefore identifies the disclosed downside tripwires without asserting they have fired; no reported figure in this filing is described as impaired, declining, or loss-bearing.

Risks and what to watch

- Reported facts: For the three-month period, Revenue from Contract with Customer, Excluding Assessed Tax moved higher year over year, reaching $1,308,400,000 USD for the three months ended June 30, 2026 versus $1,157,100,000 USD for the three months ended June 30, 2025. The six-month year-to-date revenue line, Revenue from Contract with Customer, Excluding Assessed Tax, also moved higher year over year at $2,500,300,000 USD for the six months ended June 30, 2026 against $2,193,100,000 USD for the six months ended June 30, 2025.

Net Income (Loss) Attributable to Parent followed a similar shape, with $249,100,000 USD for the three months ended June 30, 2026 versus $179,800,000 USD for the three months ended June 30, 2025, and $448,600,000 USD for the six months ended June 30, 2026 versus $285,200,000 USD for the six months ended June 30, 2025. Both periods remained profitable on a year-over-year basis. - Management explanations: The cited fair-value discussion notes that non-marketable equity investments are carried at cost less impairment, adjusted for observable price changes in orderly transactions.

Management states that "it is impracticable for us to estimate the fair value of these investments on a recurring basis" because the underlying entities are privately held. The discussion also discloses that cumulative downward adjustments and impairments were not significant and that no significant impairment losses were recorded on assets and liabilities measured at fair value on a non-recurring basis during the periods presented. - Analyst inference: The reported revenue and net income lines expand on both windows without a margin commentary in the quoted text, leaving the reader to weigh operating leverage separately.

The fair-value section explicitly leans on the lower fair-value tier for private investments, which is consistent with conservative carrying values and a low noise floor for those positions this period. - Counter-evidence: The filing evidence offers none in the form of segment, geography, or product detail that would let a reader challenge the headline growth. The filing evidence contains no peer or industry comparison.

The filing evidence also lacks segment-level detail for revenue, so any inference about a single end market rests outside the filing. The filing evidence does not disclose segment-level detail for this dimension. - Unknowns: The filing does not attribute the revenue and net income changes to a specific cause.

The filing evidence does not attribute this change to any single cause. The fair-value narrative leaves the reader without a recurring mark-to-market for the private investments, so any future impairment or upward adjustment would arrive as a discrete event rather than a smooth trend. - Metrics to watch next period: revenue growth on both the three-month and six-month windows, the trajectory of net income to confirm the profit-to-profit transitions continue, any disclosure of fair-value changes on non-marketable equity investments given the cited note's reliance on observable price changes, and the carry-forward of any cumulative upward or downward adjustments now sitting in other assets.

A useful cross-check for readers is the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in the reporting period Filing insight, which applies a similar profit-to-profit framing to a different issuer for context.